These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429 [TBL] [Abstract][Full Text] [Related]
4. Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes. Casey L; Singh N Surg Pathol Clin; 2019 Jun; 12(2):515-528. PubMed ID: 31097113 [TBL] [Abstract][Full Text] [Related]
5. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. McCluggage WG Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157 [TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas]. Shen XX; Yu L; Bi R; Yang WT Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637 [TBL] [Abstract][Full Text] [Related]
8. The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary. Wong KK; Gershenson D Dis Markers; 2007; 23(5-6):377-87. PubMed ID: 18057521 [TBL] [Abstract][Full Text] [Related]
9. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
10. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839 [TBL] [Abstract][Full Text] [Related]
11. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350 [TBL] [Abstract][Full Text] [Related]
12. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma]. Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343 [TBL] [Abstract][Full Text] [Related]
13. Low-grade serous carcinoma: molecular features and contemporary treatment strategies. Angarita AM; Cholakian D; Fader AN Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191 [TBL] [Abstract][Full Text] [Related]
14. Low-grade serous tumors of ovary. Bell DA Int J Gynecol Pathol; 2014 Jul; 33(4):348-56. PubMed ID: 24901394 [TBL] [Abstract][Full Text] [Related]
15. Low-grade Serous Neoplasia of the Female Genital Tract. Folkins AK; Longacre TA Surg Pathol Clin; 2019 Jun; 12(2):481-513. PubMed ID: 31097112 [TBL] [Abstract][Full Text] [Related]
16. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Vang R; Shih IeM; Salani R; Sugar E; Ayhan A; Kurman RJ Am J Surg Pathol; 2008 Nov; 32(11):1667-74. PubMed ID: 18769340 [TBL] [Abstract][Full Text] [Related]
17. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090 [TBL] [Abstract][Full Text] [Related]